Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) EBITDA Margin (2019 - 2025)

Revolution Medicines has reported EBITDA Margin over the past 6 years, most recently at 2975.78% for Q4 2025.

  • Quarterly results put EBITDA Margin at 2975.78% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 141402.05% (changed N/A YoY), and the annual figure for FY2023 was 3748.21%, down 304129.0%.
  • EBITDA Margin for Q4 2025 was 2975.78% at Revolution Medicines, down from 2654.81% in the prior quarter.
  • Over the last five years, EBITDA Margin for RVMD hit a ceiling of 2654.81% in Q3 2025 and a floor of 21579.78% in Q4 2023.
  • Median EBITDA Margin over the past 4 years was 764.7% (2022), compared with a mean of 2785.79%.
  • Biggest five-year swings in EBITDA Margin: surged 254813bps in 2022 and later tumbled -2117726bps in 2023.
  • Revolution Medicines' EBITDA Margin stood at 559.33% in 2021, then rose by 28bps to 402.52% in 2022, then crashed by -5261bps to 21579.78% in 2023, then surged by 86bps to 2975.78% in 2025.
  • The last three reported values for EBITDA Margin were 2975.78% (Q4 2025), 2654.81% (Q3 2025), and 21579.78% (Q4 2023) per Business Quant data.